Alaska Alliance for Community Engagement Phase II: Partnership for Action Toward Health (AK ACE-PATH)
Alaska Alliance for Community Engagement Phase II: Protecting Health in the American Arctic: Implementing Localized Solutions to Promote Health and Prevent Chronic Disease in Rural Alaska
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Stacy Rasmus, PhD
- Telefonnummer: 907-328-8919
- E-mail: smrasmus@alaska.edu
Undersøgelse Kontakt Backup
- Navn: Hannah Robinson, MPH
- Telefonnummer: 731-400-3539
- E-mail: hrobinson3@alaska.edu
Studiesteder
-
-
Alaska
-
Fairbanks, Alaska, Forenede Stater, 99775
- University of Alaska Fairbanks
-
Kontakt:
- Maria Stejskal
- Telefonnummer: 907-474-6230
- E-mail: mtrussell@alaska.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Self-identify as a permanent resident of the study community
- Be a youth between the ages of 12-17 years or an adult 18+
- Be able to provide written informed consent
Exclusion Criteria:
- Does not have permanent residence in the community or has lived in the community less than 5 years
- Is unable to provide written informed consent
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Enrollment in TAHP
The study will enroll 360 participants from four unique community settings to receive the TAHP intervention.
The study design will make use of a dynamic wait-listed design (DWLD) with 360 participants assessed with behavioral and community-level measures at four time points: baseline (B), intervention midpoint (T1), Intervention end (T2) and 12-month follow-up (T3).
|
The TAHP intervention will utilize a valid measure of rural AN community-level protective factors (Allen, et al., 2025), and an evidence-based toolkit containing strategies proven to increase mental health and well-being in rural AN communities (Allen, Charles, et al., 2023).
A formalized community engaged process will generate new intervention activities that integrate cutting-edge science to address local health priorities.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Perceived Stress Scale Questionnaire will measure individual-level indicators of stress that we hypothesize will decrease over time with intervention participation
Tidsramme: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The NIH Toolbox Perceived Stress Scale is a standardized tool designed to assess how unpredictable, uncontrollable, and overloaded individuals feel in their lives.
We will analyze how individual stress indicators are mitigated over time by intervention participation.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
General Life Satisfaction Scale will measure individual level indicators of life satisfaction that we hypothesize will increase with intervention participation
Tidsramme: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The NIH Toolbox General Life Satisfaction Scale is a tool designed to assess an individual's cognitive evaluation of their life experiences and overall satisfaction.
We will assess how the intervention mitigates life satisfaction with individuals who participate.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess if depression decreases with intervention participation using the PHQ-9 Questionnaire
Tidsramme: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Patient Health Questionnaire 9 (PHQ-9) measures the frequency of depressed mood and anhedonia over the past two weeks.
We will assess how the intervention impacts depressive symptoms with individual participation.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess if anxiety symptoms decrease with intervention participation using the GAD-7
Tidsramme: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Generalized Anxiety Disorder 7-Item (GAD-7) Screener will be given at every time point to assess how the intervention mitigates anxiety with individual participants
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess if food security increases using the food security index from the PhenX Toolkit
Tidsramme: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The PhenX Toolkit includes standardized measures for assessing food security, which is crucial for understanding social determinants of health.
We will use items from the standardized food security tools to evaluate how food access impacts health outcomes and if food security increases with individual participation in the intervention.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess if cultural efficacy increases with individual intervention participation using the Cultural Efficacy Scale.
Tidsramme: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Cultural Efficacy Scale developed by Gonzalez, Sittner, and Walls in 2022 measures individuals' comfort and access to cultural and traditional resources, particularly within Indigenous communities.
This scale consists of 7-8 items, each with a range of response options from "strongly disagree" to "strongly agree."
We will analyze the data to link cultural efficacy with mental health outcomes (depression and anxiety), highlighting the protective effects of engagement in the intervention.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess how the intervention increases individual protective factors using the Multi-Cultural Mastery Scale
Tidsramme: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Multicultural Mastery Scale, developed by Allen and Mohatt, assesses coping strategies through self-mastery and communal mastery dimensions.
It includes subscales that differentiate between mastery related to family and friends, highlighting the importance of social networks.
We will utilize data from this scale to determine how the intervention increases positive coping and builds social networks connections in individuals who participate.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess how intervention participation increases social and cultural connectedness using the Awareness of Connectedness Scale
Tidsramme: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Awareness of Connectedness Scale (ACS), developed by Mohatt and Fok, measures an individual's awareness of their interrelatedness with family, community, and the natural environment.
This scale is particularly focused on cultural aspects of wellness and healing among Alaska Native people, providing insights into their social and ecological connections.
We will utilize data from the scale to assess the intervention impacts on building connectedness among individual participants.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess how the intervention increases reasons for life and meaning and purpose using the Reasons for Life Scale
Tidsramme: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Reasons for Life Scale (RFL), developed by Allen and Rasmus, focuses on cultural strengths and protective factors against suicide, particularly among Alaska Native people.
It emphasizes resilience, cultural teachings, and community recognition as vital components in promoting mental health and preventing suicide.
We will utilize data from scale to assess how the intervention promotes reasons for life and associates with mental health outcomes (depression and anxiety) in individuals who participate in activities.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
We will assess the increase in community-level factors that are protective and contribute to health outcomes using the Protective Community Scale
Tidsramme: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Protective Community Scale (PCS), developed by Wexler, Allen, and Rasmus, aims to identify community-level protective factors that can reduce suicide risk among Alaska Native youth.
This scale is part of a broader effort to enhance resilience in these communities through culturally relevant measures and community engagement.
We will analyze data from the PCS to determine if the intervention has mitigated environmental stressors and increased community protection.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
We will assess changes to a stress biomarker, cortisol, using Salimetrics OnTimePoint SalivaTM Collection Management application system.
Tidsramme: Day 1 (baseline), 8 months (T2) and at 20 months (T3)
|
To measure the impacts of our intervention on biological outcomes, we will assess biomarkers associated with allostatic load - cortisol as an indicator of physiological stress response.
These biomarkers will allow us to evaluate whether participation in the intervention is associated with reduced chronic stress burden and improved mental health (anxiety and depression) over time.
Our proposed saliva collection protocol will involve our research team members administering the saliva kits with youth and adult participants over a 3-day period with multiple tests to capture cortisol levels throughout the day.
Multi-day cortisol levels will be averaged to determine a baseline, and the same process will be used for saliva collection and measurement of cortisol levels at each time point.
|
Day 1 (baseline), 8 months (T2) and at 20 months (T3)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 6922-06-CH-S001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .